TAK-385, an oral GnRH antagonist: efficacy and safety results from a randomized phase 2 trial in prostate cancer patients (pts)

Date 26 September 2015
Event European Cancer Congress 2015
Session Genitourinary Malignancies - Prostate Cancer
Topics Prostate Cancer
Presenter Shore, N.